Team
Team
BB3008, an investigational Hematopoietic Progenitor Kinase 1 (HPK1) inhibitor independently discovered and developed by BroadenBio, has been selected as the "Late-Breaking Research" at the 2023 annual meeting of the American Association for Cancer Research (AACR) recently. The preclinical data of BB3008 will be presented in the poster session on April 19, 2023. The information has been published on the AACR official website.
Detailed Information
Title: BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Session Date and Time: Wednesday Apr 19, 2023 9:00 AM - 12:30 PM
Location: Poster Section 35
Poster Board Number: 15
Abstract Presentation Number: LB324
About AACR
The American Association for Cancer Research (AACR) annual meeting is one of the largest worldwide academic conferences on international cancer research. The conference focuses on the latest progress in various fields of cancer research, releases innovative target research, preclinical data and early clinical trial results, and promotes exchanges and cooperation among cancer researchers around the world. The 2023 annual meeting will be held at the Orange County Convention Center in Orlando, Florida, U.S. from April 14 to 19, 2023.
address：
A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176
phone：
Copyright ©2019 BroadenBio